...
首页> 外文期刊>Intensive care medicine >Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.
【24h】

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.

机译:在基于红霉素的促动疗法治疗不耐受的危重患者中,艰难梭菌腹泻的风险。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine the incidence of Clostridium difficile (CD) diarrhoea in feed-intolerant, critically ill patients who received erythromycin-based prokinetic therapy. DESIGN AND SETTING: Prospective observational study in a mixed intensive care unit. METHODS: The development of diarrhoea (>[Symbol: see text]3 loose, liquid stool per day with an estimated total volume[Symbol: see text]>/=[Symbol: see text]250[Symbol: see text]ml/day) was assessed in 180 consecutive critically ill patients who received prokinetic therapy (erythromycin only, n[Symbol: see text]=[Symbol: see text]53; metoclopramide, n[Symbol: see text]=[Symbol: see text]37; combination erythromycin/metoclopramide, n[Symbol: see text]=[Symbol: see text]90) for feed intolerance. Stool microscopy, culture and CD toxin assay were performed in all patients who developed diarrhoea during and after prokinetic therapy. Diarrhoea was deemed to be related to CD infection if CD toxin was detected. RESULTS: Demographics, antibiotic use and admission diagnosis were similar amongst the three patients groups. Diarrhoea developed in 72 (40%) patients, 9.9[Symbol: see text]+/-[Symbol: see text]0.8[Symbol: see text]days after commencement of therapy, none of whom was positive for CD toxin or bacterial infection. Parasitic infections were found in four aboriginal men from an area endemic for these infections. Diarrhoea was most prevalent in patients who received combination therapy (49%) and was more common than in those who received erythromycin alone (30%) and metoclopramide alone (32%). Diarrhoea was short-lasting with a mean duration of 3.6[Symbol: see text]+/-[Symbol: see text]1.2[Symbol: see text]days. CONCLUSIONS: In critical illness, diarrhoea following the administration of erythromycin at prokinetic doses is not associated with CD but may be related to pro-motility effects of the agent. Prokinetic therapy should be stopped at the onset of diarrhoea and prophylactic use should be strictly avoided.
机译:目的:确定难免进食危重病且接受红霉素促动疗法的艰难梭菌(CD)腹泻的发生率。设计与地点:在混合重症监护病房中进行前瞻性观察研究。方法:腹泻的发展(> [符号:参见文字]每天3片稀疏的液体大便,估计总体积[符号:参见文字]> / = [符号:参见文字] 250 [符号:参见文字] ml /一天)在接受运动疗法治疗的180例重症患者中进行了评估(仅红霉素,n [Symbol:参见文本] = [Symbol:参见文本] 53;甲氧氯普胺,n [Symbol:参见文本] = [Symbol:参见文本] 37;红霉素/甲氧氯普胺的组合,n [符号:参见文本] = [符号:参见文本] 90),用于饲料不耐受。对所有在运动疗法期间和之后出现腹泻的患者进行粪便显微镜检查,培养和CD毒素测定。如果检测到CD毒素,则认为腹泻与CD感染有关。结果:三个患者组的人口统计学,抗生素使用和入院诊断相似。在开始治疗的几天后,有72(40%)例腹泻9.9 [符号:参见文本] +/- [符号:参见文本] 0.8 [符号:参见文本]治疗开始后几天,没有人对CD毒素或细菌感染呈阳性。在来自这些感染流行地区的四名原住民男子中发现了寄生虫感染。腹泻在接受联合治疗的患者中最为普遍(49%),比仅接受红霉素(30%)和单独使用甲氧氯普胺(32%)的患者更为普遍。腹泻持续时间短,平均持续时间为3.6 [符号:参见文本] +/- [符号:参见文本] 1.2 [符号:参见文本]天。结论:在重症疾病中,以促红剂量服用红霉素后的腹泻与CD无关,但可能与该药的促动力作用有关。腹泻发作时应停止促动疗法,并应严格避免预防性使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号